Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + azacitidine + prednisone + cyclophosphamide + thalidomide for PTCL in patients intolerant to standard chemotherapy
ChiCTR2600134410Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tucidinostat, azacitidine, prednisone, cyclophosphamide and thalidomide in peripheral T-cell lymphoma (PTCL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Objective Response Rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
tucidinostatazacitidineprednisonecyclophosphamidethalidomide
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR2600134410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134410.